Sommario

• • ·Rethinking trial eligibility in the NCD era

    Pagina :233

     
• • ·Nivolumab for advanced squamous cell lung cancer: what are the next steps?

    Pagina :234-235

    Ramon Andrade de Mello, Inés Pousa, Deolinda Pereira

     
• • ·Can older women with early breast cancer avoid radiation?

    Pagina :235-237

    Kevin S Hughes, Lauren A Schnaper

     
• • ·Hypofractionated radiotherapy in prostate cancer

    Pagina :237-238

    David P Dearnaley

     
• • ·PET-adapted salvage therapy in Hodgkin’s lymphoma

    Pagina :239-240

    Umberto Tirelli, Michele Spina

     
• • ·Prognostic accuracy in second-line renal cancer therapy

    Pagina :240-241

    Axel Bex

    
• • ·Bevacizumab and quality of life in advanced cervical cancer

    Pagina :241-243

    David Cella

     
• • ·Trabectedin tactics: from sea squirts to sarcomas

    Pagina :243-244

    R Lor Randall, Matthew G Cable

     
• • ·Androgen deprivation with radiotherapy: how long is long enough?

    Pagina :244-246

    Phillip J Gray, Anthony L Zietman

     
• • ·Necitumumab for patients with non-squamous NSCLC: uninspiring results

    Pagina :246-247

    Fei Zhou, Caicun Zhou

     
• • ·Moving the goal posts in prostate cancer trials

    Pagina :247-249

    Ravi A Madan, James L Gulley

     
• • ·Stereotactic radiosurgery alone for brain metastases

    Pagina :249-250

    Arjun Sahgal, David Larson, Jonathan Knisely

     
• • ·Japanese universal health care faces a crisis in cancer treatment

    Pagina :251-252

    Yasuhiro Fujiwara, Kan Yonemori, Taro Shibata, Natsuko Okita, Nobuko Ushirozawa

     
• • ·Japanese regulatory authority’s perspective on biosimilars

    Pagina :e101

    Sumimasa Nagai, Reiko Yanagihara, Yasuhiro Kishioka

    
• • ·Japanese regulatory authority’s perspective on biosimilars – Authors’ reply

    Pagina :e102

    Charles L Bennett, Brian Chen, Terhi Hermanson, Peter Georgantopoulos, Oliver A Sartor

    
• • ·Body-mass index, cancer, and implications for screening

    Pagina :e102

    Clarisse Eveno, Yann Parc, Alexis Laurent, Michel Ducreux, Marc Pocard

    
• • ·Adjuvant chemotherapy in locally advanced bladder cancer

    Pagina :e103

    Kevin Lu

    
• • ·The oncological package: a new source of concern in Poland’s health system

    Pagina :e104

    Tomasz Holecki, Piotr Romaniuk

    
• • ·Correction to Lancet Oncol 2015; 16: 133

    Pagina :e105

    
• • ·Correction to Lancet Oncol 2015; 16: 266

    Pagina :e105

    
• • ·Correction to Lancet Oncol 2015; 16: 181, 184

    Pagina :e105

    
• • ·Correction to Lancet Oncol 2015; 16: 274

    Pagina :e105

    
• • ·Correction to Lancet Oncol 2015; 16: 237

    Pagina :e105

    
• • ·Less surgery improves survival for advanced colorectal cancer

    Pagina :e106

    Sanjay Tanday

     
• • ·Unmet needs of cancer survivors

    Pagina :e106

    Talha Khan Burki

    
• • ·Targeted biopsy boosts detection of high-risk prostate cancer

    Pagina :e107

    Sanjay Tanday

     
• • ·Side-effects of cancer drugs are under-reported in trials

    Pagina :e107

    Susan Mayor

    
• • ·Nivolumab shows clinical activity in Hodgkin’s lymphoma

    Pagina :e108

    Sanjeet Bagcchi

     
• • ·UK and US governments to fund personalised medicine

    Pagina :e108

    Talha Burki

     
• • ·Lifetime risk of cancer is more than 50% in Britain

    Pagina :e109

    Sanjay Tanday

     
• • ·Minimally invasive test for Barrett’s oesophagus

    Pagina :e109

    Sanjeet Bagcchi

    
• • ·Canada removes ban on physician-assisted suicide

    Pagina :e110

    Talha Khan Burki

     
• • ·Lenvatinib improves survival in refractory thyroid cancer

    Pagina :e110

    Susan Mayor

    
• • ·Large degree of mutation in paediatric brain tumours

    Pagina :e111

    Talha Khan Burki

     
• • ·HPV vaccination unlikely to promote risky sexual behaviours

    Pagina :e111

    Sanjeet Bagcchi

    
• • ·Hormone therapy increases ovarian cancer risk

    Pagina :e112

    Sanjay Tanday

     
• • ·Gene mutation order affects cancer behaviour

    Pagina :e112

    Sanjeet Bagcchi

    
• • ·Cruel imitation

    Pagina :253-254

    Peter Ranscombe

     
• • ·Wild: a journey through wilderness and memory

    Pagina :254-255

    Hannah Cagney

     
• • ·A stoic irreducibility: I Am Not The Cancer

    Pagina :255-256

    Josef James Pitt-Rashid

     
• • ·The art of living to the last

    Pagina :256

    Sanjeet Bagcchi

     
• • ·Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Pagina :257-265

    Naiyer A Rizvi, Julien Mazières, David Planchard, Thomas E Stinchcombe, Grace K Dy, Scott J Antonia, Leora Horn, Hervé Lena, Elisa Minenza, Bertrand Mennecier, Gregory A Otterson, Luis T Campos, David R Gandara, Benjamin P Levy, Suresh G Nair, Gérard Zalcman, Jürgen Wolf, Pierre-Jean Souquet, Editta Baldini, Federico Cappuzzo, Christos Chouaid, Afshin Dowlati, Rachel Sanborn, Ariel Lopez-Chavez, Christian Grohe, Rudolf M Huber, Christopher T Harbison, Christine Baudelet, Brian J Lestini, Suresh S Ramalingam

    Riassunto Riassunto Mappa Mappa   
• • ·Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial

    Pagina :266-273

    Ian H Kunkler, Linda J Williams, Wilma J L Jack, David A Cameron, J Michael Dixon, on behalf of the PRIME II investigators

    Riassunto Riassunto Mappa Mappa   
• • ·Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial

    Pagina :274-283

    Shafak Aluwini, Floris Pos, Erik Schimmel, Emile van Lin, Stijn Krol, Peter Paul van der Toorn, Hanja de Jager, Maarten Dirkx, Wendimagegn Ghidey Alemayehu, Ben Heijmen, Luca Incrocci

    Riassunto Riassunto Mappa Mappa   
• • ·PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study

    Pagina :284-292

    Alison J Moskowitz, Heiko Schöder, Joachim Yahalom, Susan J McCall, Stephanie Y Fox, John Gerecitano, Ravinder Grewal, Paul A Hamlin, Steven Horwitz, Rachel Kobos, Anita Kumar, Matthew Matasar, Ariela Noy, M Lia Palomba, Miguel-Angel Perales, Carol S Portlock, Craig Sauter, Neerav Shukla, Peter Steinherz, David Straus, Tanya Trippett, Anas Younes, Andrew Zelenetz, Craig H Moskowitz

    Riassunto Riassunto Mappa Mappa   
• • ·The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

    Pagina :293-300

    Jenny J Ko, Wanling Xie, Nils Kroeger, Jae-lyun Lee, Brian I Rini, Jennifer J Knox, Georg A Bjarnason, Sandy Srinivas, Sumanta K Pal, Takeshi Yuasa, Martin Smoragiewicz, Frede Donskov, Ravindran Kanesvaran, Lori Wood, D Scott Ernst, Neeraj Agarwal, Ulka N Vaishampayan, Sun-young Rha, Toni K Choueiri, Daniel Y C Heng

    Riassunto Riassunto Mappa Mappa   
• • ·Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240)

    Pagina :301-311

    Richard T Penson, Helen Q Huang, Lari B Wenzel, Bradley J Monk, Sharon Stockman, Harry J Long, Lois M Ramondetta, Lisa M Landrum, Ana Oaknin, Thomas J A Reid, Mario M Leitao, Michael Method, Helen Michael, Krishnansu S Tewari

    Riassunto Riassunto Mappa Mappa   
• • ·Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial

    Pagina :312-319

    Axel Le Cesne, Jean-Yves Blay, Julien Domont, Emmanuelle Tresch-Bruneel, Christine Chevreau, François Bertucci, Corinne Delcambre, Esma Saada-Bouzid, Sophie Piperno-Neumann, Jacques-Olivier Bay, Olivier Mir, Isabelle Ray-Coquard, Thomas Ryckewaert, Thibaud Valentin, Nicolas Isambert, Antoine Italiano, Stéphanie Clisant, Nicolas Penel

    Riassunto Riassunto Mappa Mappa   
• • ·High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial

    Pagina :320-327

    Almudena Zapatero, Araceli Guerrero, Xavier Maldonado, Ana Alvarez, Carmen Gonzalez San Segundo, Maria Angeles Cabeza Rodríguez, Victor Macias, Agustí Pedro Olive, Francesc Casas, Ana Boladeras, Carmen Martín de Vidales, Maria Luisa Vazquez de la Torre, Salvador Villà, Aitor Perez de la Haza, Felipe A Calvo

    Riassunto Riassunto Mappa Mappa   
• • ·Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

    Pagina :328-337

    Luis Paz-Ares, Jörg Mezger, Tudor E Ciuleanu, Jürgen R Fischer, Joachim von Pawel, Mariano Provencio, Andrzej Kazarnowicz, György Losonczy, Gilberto de Castro, Aleksandra Szczesna, Lucio Crino, Martin Reck, Rodryg Ramlau, Ernst Ulsperger, Christian Schumann, Jose Elias A Miziara, Álvaro E Lessa, Mircea Dediu, Beatrix Bálint, Henrik Depenbrock, Victoria Soldatenkova, Raffael Kurek, Fred R Hirsch, Nick Thatcher, Mark A Socinski, for the INSPIRE investigators †

    Riassunto Riassunto Mappa Mappa   
• • ·Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial

    Pagina :338-348

    Fred Saad, Karim Fizazi, Viorel Jinga, Eleni Efstathiou, Peter C Fong, Lowell L Hart, Robert Jones, Raymond McDermott, Manfred Wirth, Kazuhiro Suzuki, David B MacLean, Ling Wang, Hideyuki Akaza, Joel Nelson, Howard I Scher, Robert Dreicer, Iain J Webb, Ronald de Wit, for the ELM-PC 4 investigators †

    Riassunto Riassunto Mappa Mappa   
• • ·Radiation therapy in the locoregional treatment of triple-negative breast cancer

    Pagina :e113

    Meena S Moran

    Riassunto Riassunto Mappa Mappa  
• • ·Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group

    Pagina :e123

    Saro H Armenian, Melissa M Hudson, Renee L Mulder, Ming Hui Chen, Louis S Constine, Mary Dwyer, Paul C Nathan, Wim J E Tissing, Sadhna Shankar, Elske Sieswerda, Rod Skinner, Julia Steinberger, Elvira C van Dalen, Helena van der Pal, W Hamish Wallace, Gill Levitt, Leontien C M Kremer

    Riassunto Riassunto Mappa Mappa   
• • ·Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014

    Pagina :e137

    Sandra R Distelhorst, James F Cleary, Patricia A Ganz, Nuran Bese, Rolando Camacho-Rodriguez, Fatima Cardoso, Henry Ddungu, Julie R Gralow, Cheng-Har Yip, Benjamin O Anderson, on behalf of the Breast Health Global Initiative Global Summit on Supportive Care, Quality of Life Consensus Panel Members

    Riassunto Riassunto Mappa Mappa  
• • ·Morphogenetic fields of embryonic development in locoregional cancer spread

    Pagina :e148

    Michael Höckel

    Riassunto Riassunto Mappa Mappa